Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
CNS Stimulant (Prodrug) — Schedule 2 Controlled Drug (ADHD / Binge Eating Disorder)

Lisdexamfetamine

Brand names: Vyvanse, Elvanse

Lisdexamfetamine is a central nervous system stimulant prodrug of dexamfetamine, licensed for attention deficit hyperactivity disorder (ADHD).

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is converted in the body to dexamfetamine, which increases synaptic noradrenaline and dopamine by promoting their release and inhibiting reuptake.

Prescribing in practice

  • It can raise blood pressure and heart rate and is associated with cardiovascular risk, so cardiovascular status must be assessed before treatment and it should be avoided in significant cardiac disease.
  • As a controlled stimulant it carries a potential for misuse and dependence and requires careful prescribing and monitoring.
  • Monitor growth in children and young people, as appetite suppression and weight effects can occur.

Monitoring

Monitor blood pressure, heart rate, weight and height (in children), appetite, sleep and mental state at baseline and regularly during treatment.

Counselling the patient

  • Explain that the medicine helps focus and behaviour but does not cure ADHD.
  • Report palpitations, chest pain, breathlessness or mood changes.
  • Take in the morning to reduce the risk of insomnia.

Evidence & guidelines

NICE recommends stimulants including lisdexamfetamine as options for ADHD, with cardiovascular assessment and growth monitoring as part of standard care.

Reference: NICE NG87 (ADHD); NICE NG123 (BED); Elvanse SPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways